ADC Biotechnology is creating innovative new technology, which aims to speed up, simplify and significantly lower the costs of the processes involved in the production of new antibody drug conjugates (ADCs). ADCs are antibodies that are attached to cancer-killing drugs using chemical ‘linkers’, allowing for targeted treatment of cancerous tissue.
Meet the team
Downing LLP launches 'knowledge intensive' EIS fund to fuel entrepreneurial healthcare businesses in wake of Covid-19
Specialist tax-efficient investment manager Downing LLP is pleased to announce the launch of a new Enterprise ...